BetterLife Announces Debt Conversions
10 mars 2025 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
07 mars 2025 09h00 HE
|
Alvotech
REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Groupe PAT : Hausse du Chiffre d’Affaires Combiné 2024
28 févr. 2025 12h30 HE
|
Plant Advanced Technologies
Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de pressePour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à...
Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung
24 févr. 2025 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) birtir uppgjör fyrir fjórða ársfjórðung 2024 og ársuppgjör 2024 miðvikudaginn 26. mars nk. eftir lokun markaða. Uppgjörsfundur með greinendum, sem sendur er út í beinum...
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
24 févr. 2025 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
28 janv. 2025 07h00 HE
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
27 janv. 2025 06h00 HE
|
Alvotech
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
23 janv. 2025 07h00 HE
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo® in Central & Eastern Europe
14 janv. 2025 08h00 HE
|
Er-Kim
Er-Kim's partnership will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease
USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
14 janv. 2025 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...